• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WuXi Cuts U.S. Manufacturing Business

WuXi Cuts U.S. Manufacturing Business

December 3, 2008
CenterWatch Staff

Chinese contract research organization (CRO) WuXi PharmaTech is discontinuing its U.S. biologics manufacturing operations as of December 31. As a result, the company will cut about 100 manufacturing and supporting positions at its Philadelphia facility.

“Given the depressed demand and the high cost structure of our biologics manufacturing services, we will focus on expanding our biologics testing, cell banking and cell therapy services in our Philadelphia site instead,” said WuXi CFO Benson Tsang in an investor conference call yesterday.

WuXi acquired the Philadelphia manufacturing operations as part of its January 2008 acquisition of AppTec, a U.S.-based laboratory services provider. Although company executives were initially optimistic about the potential for U.S.-based manufacturing, year-end 2008 forecasts have biologics manufacturing revenues at less than 4% of total expected annual revenue.

A company executive said in Tuesday’s call that the biologics manufacturing business is relatively risky, and when the economy takes a downturn, biotech companies just don’t have the financing for it. He said WuXi doesn’t see a turnaround in the foreseeable future.

The CRO will begin cutting manufacturing operations this month to be completed by early spring 2009. The restructuring will cost the company between $2.5 million and $3.5 million in the next few months, according to Tsang, but it will result in an annual cost-savings of approximately $10 million.

The discontinuation of U.S.-based biologics manufacturing does not eliminate WuXi from the manufacturing business altogether. Tsang told investors Tuesday that the company would begin to test run a large-scale manufacturing facility in China by the end of this year, with plans to provide commercial Active Pharmaceutical Ingredients manufacturing services in 2009.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing